文献速递淋巴瘤血栓与止血

奥妥珠单抗治疗初诊滤泡性淋巴瘤患者急性血小板减少的临床特征

[Clinical characteristics of acute thrombocytopenia in newly diagnosed follicular lymphoma patients receiving obinutuzumab chemotherapy].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

该回顾性研究纳入167例接受G-CHOP或GB方案一线治疗的初诊滤泡性淋巴瘤患者,评估奥妥珠单抗诱导的急性血小板减少(OIAT)的临床特征及危险因素。结果显示38.9%发生OIAT,中位发生时间为首次用药后1.0天,结外受累、FLIPI-2评分>3分及基线PLT<150×10^9/L为独立危险因素。3~4级OIAT恢复时间显著延长且非血液学不良事件发生率更高,升血小板治疗未见显著缩短恢复时间。

要点

  • OIAT发生率为38.9%,多发生于首次用药后1天,3~4级占27.7%。
  • 结外受累、FLIPI-2>3分、基线PLT<150×10^9/L为独立危险因素。
  • 3~4级OIAT恢复时间延长且非血液学不良事件更多,需密切监测。

核心结论

  • OIAT常见于首次用药后,基线肿瘤负荷高和免疫状态低的患者风险显著增加。
  • 1~2级血小板减少可观察随访,3~4级需密切监测并积极干预。

研究设计与样本

  • 回顾性纳入2021年1月至2024年12月江苏省人民医院167例初诊FL患者,接受G-CHOP或GB方案治疗。

主要发现

  • 65例(38.9%)发生OIAT,其中18例(27.7%)为3~4级血小板减少。
  • OIAT中位发生时间为首次用药后1.0(1.0,2.0)天,中位恢复时间为8.0(6.0,16.0)天。
  • 多因素分析显示结外受累(OR=3.395,95%CI:1.229~9.378,P=0.018)、FLIPI-2评分>3分(OR=3.622,95%CI:1.192~10.973,P=0.023)、基线PLT<150×10^9/L(OR=3.216,95%CI:1.122~9.215,P=0.030)为独立危险因素。

关键数值与推荐

  • 3~4级OIAT患者PLT恢复时间较1~2级显著延长[中位数:16.0(8.0,18.5)天对7.0(5.0,12.8)天,P=0.010]。
  • 3~4级OIAT患者非血液学不良事件发生率更高[72.2%(13/18)对40.4%(19/47),P<0.001]。
  • 升血小板治疗对1~2级及3~4级OIAT的PLT恢复时间均无显著影响(P=0.338和P=0.420)。

临床怎么用

  • 识别具有结外受累、FLIPI-2>3分、基线PLT<150×10^9/L的高危患者并实施分层管理。
  • 1~2级OIAT可观察随访,3~4级需密切监测并积极干预。

局限性

  • 本研究为单中心回顾性研究,样本量有限,结论需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of first-line immunochemotherapy with obinutuzumab in patients with follicular lymphoma (FL), with a particular focus on the clinical characteristics and potential risk factors of obinutuzumab-induced acute thrombocytopenia (OIAT) . Methods: The present retrospective study included 167 newly diagnosed FL patients receiving G-CHOP or GB regimens at Jiangsu Provincial People's Hospital between January 2021 and December 2024. The patients' baseline clinical characteristics and serial platelet (PLT) count were collected. In patients with OIAT, the nadir PLT count and recovery time were recorded. Logistic regression analysis was performed to identify the risk factors for OIAT. Results: Among the 167 patients, 65 (38.9%) developed OIAT, including 18 (27.7%) patients with grade 3-4 thrombocytopenia. The median time to OIAT onset was 1.0 (1.0, 2.0) days after the first administration, and the median recovery time was 8.0 (6.0, 16.0) days. Compared to patients without OIAT (102/167, 61.1%), those with OIAT had lower baseline neutrophil percentage [median: 3.4 (2.5, 4.9) % vs 4.3 (3.1, 6.6) %, P=0.005], lower D-dimer levels [0.2 (0.1, 0.7) mg/L vs 0.6 (0.3, 1.3) mg/L, P=0.001], higher IL-10 levels [8.0 (3.7, 32.0) ng/L vs 4.6 (2.4, 7.9) ng/L, P=0.008], higher β2-microglobulin levels [2.7 (1.8, 3.9) mg/L vs 2.2 (1.7, 3.0) mg/L, P=0.024], lower CD4(+) T cell counts [ (32.4 ± 17.6) cells/μl, vs (37.4 ± 11.8) cells/μl, P=0.043], and lower IgA levels [1.2 (1.0, 2.1) g/L vs 1.6 (1.2, 2.2) g/L, P=0.045]. Multivariate analysis showed that extranodal involvement (OR=3.395, 95% CI: 1.229-9.378, P=0.018), FLIPI-2 score >3 (OR=3.622, 95% CI: 1.192-10.973, P=0.023), and baseline PLT count of <150×10(9)/L (OR=3.216, 95% CI: 1.122-9.215, P=0.030) were the independent risk factors for OIAT. In patients with grade 1-2 and 3-4 OIAT, the use of thrombopoietic therapy had no significant effect on prolonged PLT recovery time [grade 1-2: median: 7.1 (5.0, 12.5) days vs 7.4 (5.2, 13.0) days, P=0.338; grades 3-4: (21.0 ± 14.4) days vs (15.5 ± 9.9) days, P=0.420]. However, patients with grade 3-4 OIAT had significantly prolonged PLT recovery time [median: 16.0 (8.0, 18.5) days vs 7.0 (5.0, 12.8) days, P=0.010] and were more likely to experience non-hematologic adverse events[incidence rate: 72.2% (13/18) vs 40.4% (19/47), P<0.001]. Conclusion: OIAT commonly occurs after the initial drug administration, with the risk significantly increased in patients with high baseline tumor burden and impaired immune status. Grade 1-2 thrombocytopenia may be observed during follow-up, whereas Grade 3-4 cases require close monitoring and active intervention. Identifying high-risk patients and implementing stratified management strategies can help optimize treatment safety. 目的: 评估奥妥珠单抗一线免疫化疗在滤泡性淋巴瘤(FL)患者中的疗效及安全性并探讨奥妥珠单抗诱导的急性血小板减少(OIAT)的临床特征及其潜在危险因素。 方法: 回顾性纳入2021年1月至2024年12月江苏省人民医院收治的167例初诊FL患者,接受G-CHOP方案(奥妥珠单抗+环磷酰胺+多柔比星+长春新碱+泼尼松)或GB方案(奥妥珠单抗+苯达莫司汀)治疗。采用二元Logistic回归分析发生OIAT的影响因素。收集患者基线资料及治疗后血小板计数(PLT),记录发生OIAT患者的PLT最低值及恢复情况。 结果: 纳入的167例患者中,65例(38.9%)发生OIAT,其中18例(27.7%)为3~4级血小板减少。OIAT中位发生时间为首次用药后1.0(1.0,2.0)d,中位恢复时间为8.0(6.0,16.0)d。与未发生OIAT组(102/167,61.1%)相比,OIAT组基线中性粒细胞百分比[中位数:3.4(2.5,4.9)%对4.3(3.1,6.6)%,P=0.005]、D-二聚体水平[中位数:0.2(0.1,0.7)mg/L对0.6(0.3,1.3)mg/L,P=0.001)]、CD4(+)T细胞计数[(32.4±17.6)个/μl对(37.4±11.8)个/μl,P=0.043]、IgA水平[中位数:1.2(1.0,2.1)g/L对1.6(1.2,2.2)g/L,P=0.045]更低,而IL-10水平[中位数:8.0(3.7,32.0)ng/L对4.6(2.4,7.9)ng/L,P=0.008]、β2微球蛋白水平[中位数:2.7(1.8,3.9)mg/L对2.2(1.7,3.0)mg/L,P=0.024]更高。多因素分析显示,结外受累(OR=3.395,95% CI:1.229~9.378,P=0.018)、FL国际预后指数-2评分>3分(OR=3.622,95% CI:1.192~10.973,P=0.023)及基线PLT<150×10(9)/L(OR=3.216,95% CI:1.122~9.215,P=0.030)为发生OIAT的独立危险因素。1~2级与3~4级OIAT患者中升血小板治疗组较未治疗组PLT恢复时间差异无统计学意义[1~2级:中位数:7.1(5.0,12.5)d对7.4(5.2,13.0)d,P=0.338;3~4级:(21.0 ± 14.4)d对(15.5 ± 9.9)d,P=0.420];但3~4级OIAT患者较1~2级患者PLT恢复时间显著延长[中位数:16.0(8.0,18.5)d对7.0(5.0,12.8)d,P=0.010],且更易合并非血液学不良事件[发生率:72.2%(13/18)对40.4%(19/47),P<0.001]。 结论: OIAT常见于首次用药后,基线肿瘤负荷高、免疫状态低的患者发生风险显著增加。1~2级血小板减少可观察随访,3~4级需密切监测并积极干预。识别高危患者并实施分层管理有助于增加治疗安全性。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhou JX, Gao L, Xia Y, et al. [Clinical characteristics of acute thrombocytopenia in newly diagnosed follicular lymphoma patients receiving obinutuzumab chemotherapy]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42851176. doi:10.3760/cma.j.cn121090-20260225-00108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。